Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 5, 2000, Pages 1347-1353

  Cauwenberghs, Nancy ^a,b   Meiring, Muriel ^b   Vauterin, Stephan ^a   Van Wyk, Veronika ^b   Lamprecht, Seb ^b   Roodt, Jan P ^b   Novák, Levente ^c   Harsfalvi, Jolan ^c   Deckmyn, Hans ^a   Kotzé, Harry F ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Glycoprotein Ib; Monoclonal antibodies; Platelet adhesion; Platelet aggregation; Thrombosis

Indexed keywords

GLYCOPROTEIN IB; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOLCONAL ANTIBODY 6 B 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BABOON; BLEEDING TIME; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBUS;

EID: 0034101943     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.5.1347     Document Type: Article

References (42)

1. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 1993;7: 516-522.
2. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
3. Siedlecki CA, Lestini BJ, Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939-2950.
4. Clemetson KJ. Platelet collagen receptors: a new target for inhibition? Haemostasis. 1999;29:16-26.
5. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell. 1991;65:359-362.
6. Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G, Levy-Toledano S, Sultan Y, Valensi F, Bernard J. Bernard-Soulier syndrome: a new platelet glycoprotein abnormality: its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med. 1976;87:586-596.
7. Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. Thromb Haemost. 1997;78:205-209.
8. Hanson SR, Sakariassen KS. Blood flow and antithrombotic drug effects. Am Heart J. 1998;135:S132-S145.
9. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-735.
10. Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood. 1994;83:3218-3224.
11. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost. 1998;79:202-210.
12. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122:165-171.
13. Peng M, Lu W, Beviglia L, Niewiarowski S, Kirby EP. Echicetin: a snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. Blood. 1993;81:2321-2328.
14. Chang MC, Lin HK, Peng HC, Huang TF. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood. 1998;91:1582-1589.
15. Golino P, Ragni M, Cirillo P, Pascucci I, Ezekowitz MD, Pawashe A, Scognamiglio A, Pace L, Guarino A, Chiariello M. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb Haemost. 1995;74:974-979.
16. Zahger D, Fishbein MC, Garfinkel LI, Shah PK, Forrester JS, Regnstrom J, Yano J, Cercek B. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation. 1995;92:1269-1273.
17. McGhie AI, McNatt J, Ezov N, Cui K, Mower LK, Hagay Y, Buja LM, Garfinkel LI, Gorecki M, Willerson JT. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation. 1994;90: 2976-2981.
18. Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation. 1994;89:2822-2828.
19. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem. 1995;270:23352-23361.
20. 2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arterioscler Thromb. 1991;11:1231-1236.
21. Dascombe WH, Hong C, Garrett KO, White JG, Lyle VA, Miller JL, Johnson PC. Artificial microvascular graft thrombosis: the consequences of platelet membrane glycoprotein Ib inhibition and thrombin inhibition. Blood. 1993;82:126-134.
22. Becker BH, Miller JL. Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig. Blood. 1989;74:690-694.
23. Ravanat C, Freund M, Moog S, Mangin P, Azorsa D, Schwartz C, Lanza F, Cazenave J. Differential effects of monoclonal antibodies to rat GPIIb-IIIa, GPIba or GPV on platelet function and in vivo survival. Thromb Haemost. 1999;82(suppl):528a. Abstract.
24. Wicki AN, Clemetson KJ. The glycoprotein Ib complex of human blood platelets. Eur J Biochem. 1987;163:43-50.
25. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
26. Meyer S, Kresbach G, Raring P, Schumpp Vonach B, Clemetson KJ, Hadvary P, Steiner B. Expression and characterization of functionally active fragments of the platelet glycoprotein (GP) Ib-IX complex in mammalian cells: incorporation of GP Ibα into the cell surface membrane. J Biol Chem. 1993;268:20555-20562.
27. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammedinger A, Mazurier C, Deckmyn H. A new and reproducible vWF:RiCoF assay. Thromb Haemost 2000;83:107-113.
28. Fujimura Y, Titani K, Usami Y, Suzuki M, Oyama R, Matsui T, Fukui H, Sugimoto M, Ruggeri ZM. Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca. Biochemistry. 1991;30:1957-1964.
29. Harsfalvi J, Stassen JM, Hoylaerts MF, Van Houtte E, Sawyer RT, Vermylen J, Deckmyn H. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood. 1995;85:705-711.
30. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: a model of acute thrombosis in baboons. Arteriosclerosis. 1985;5:595-603.
31. 2-receptor antagonist. Thromb Haemost. 1993;70:672-675.
32. Quintero LJ, Lohre JM, Hernandez N, Meyer SC, McCarthy TJ, Lin DS, Shen SH. Evaluation of in vivo models for studying calcification behavior of commercially available bovine pericardium. J Heart Valve Dis. 1998; 7:262-267.
33. Kotze HF, Heyns AD, Lotter MG, Pieters H, Roodt JP, Sweetlove MA, Badenhorst PN. Comparison of oxine and tropolone methods for labeling human platelets with indium-111. J Nucl Med. 1991;32:62-66.
34. Fraker PJ, Speck JC. Proteins and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
35. van Wyk V, Heyns AD. Low molecular weight heparin as an anticoagulant for in vitro platelet function studies. Thromb Res. 1990;57: 601-609.
36. Ruggeri ZM. Glycoprotein Ib and von Willebrand factor in the process of thrombus formation. Ann N Y Acad Sci. 1994;714:200-210.
37. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: EPIC Investigators. Circulation. 1995;91:2882-2890.
38. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GPIβ initiates signals for platelet activation. J Clin Invest. 1991;88:1568-1573.
39. Asazuma N, Ozaki Y, Satoh K, Yatomi Y, Handa M, Fujimura Y, Miura S, Kume S. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. Blood. 1997;90:4789-4798.
40. Assoian RK, Grotendorst GR, Miller DM, Sporn MB. Cellular transformation by coordinate action of three peptide growth factors from human platelets. Nature. 1984;309:804-806.
41. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
42. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 1999;94: 172-178.